Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil crossover study for women with overactive bladder
ACTRN12622001251718Phase 2Not yet recruiting
- Sponsor
- Western Sydney Local Health District
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of tadalafil in overactive bladder (OAB) and idiopathic detrusor overactivity (IDO) (2 arms), sponsored by Western Sydney Local Health District. Primary endpoints: Change in number of incontinence episodes, Change in daytime urinary frequency and 1 more. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
tadalafil
03
Conditions
overactive bladder (OAB)idiopathic detrusor overactivity (IDO)
Beyond the preview
Go deeper on ACTRN12622001251718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001251718.